The utility of PAX8 and IMP3 immunohistochemical stains in the differential diagnosis of benign, premalignant, and malignant endocervical glandular lesions

Assessment of the Utility of PAX8 Immunohistochemical Stain in Diagnosing Endocervical Glandular Lesions

“…Earlier studies showed that PAX8 positivity ranges from 97% to 100% in AIS and 0% to 87% in ECA. [1][2][3][4][5][6][7][8][9] The discrepancies among various studies may be attributable to several factors; the first is small sample size. Our study included 43 ECA (combined 2 cohorts) and 16 AIS, and is one of the largest studies.…”

“…In a recent study, Danialan et al 8 suggested that PAX8, together with IMP3 (insulin-like growth factor-II mRNAbinding protein 3), may be used in differentiating benign endocervical glandular lesions from malignant lesions. They reported that PAX8 expression was strong and diffuse in benign conditions, and became focal and weaker in AIS and ECA.…”

“…2 Furthermore, PAX8 was expressed in 97% to 100% of adenocarcinoma in situ (AIS) and in 0% to 87% of endocervical adenocarcinoma (ECA) specimens (summarized in Table 1). 1,[3][4][5][6][7][8][9] The goal of this study was to evaluate PAX8 expression by immunohistochemistry (IHC) in endocervix.…”

Expression and utility of IMP3 in the differential diagnosis of atypical glandular cells and adenocarcinoma in liquid-based cervical cytology

“…[13][14][15]19,20 To our knowledge, there is little experience with the use of IMP3 in LBC cytology containing AGCs or Ac. In a small study by Lastra et al, 12 the ICC expression and utility of IMP3 and ProEx C (a monoclonal antibody cocktail shown to be positive in dysplastic squamous and endocervical lesions) were assessed in a cohort of 34 cases diagnosed as atypical glandular cells of undetermined significance (AGUS) on cytology and found that IMP3 was positive in 80% of glandular neoplasms and negative in 93% nonglandular lesions/cases negative for squamous intraepithelial lesion (SIL). Instead, ProEx C was positive in 60% of glandular neoplasms and negative in 83% non-glandular lesions/cases negative for SIL.…”

“…Re-expression of IMP3 has been observed in a series of human malignancies, including pancreatic, lung, pleural, gastric, colorectal, renal, bladder, ovary, and endometrial carcinoma, and in situ and invasive endocervical adenocarcinoma. [12][13][14][15] These studies have shown that IMP3 expression is not tumor-specific, but rather a good marker of malignancy. 16 To our knowledge, with the exception of one study, 17 very little experience with the use of IMP3 in liquid-based cervical (LBC) cytology demonstrating AGCs or adenocarcinoma.…”